SUMMARY The oral clonidine test was compared with the standard intravenous insulin hypoglycaemia test in 41 children and adolescents with short stature. In those without growth hormone deficiency clonidine provoked a significantly higher mean plasma growth hormone response and gave fewer false subnormal responses (apparent growth hormone deficiency) than insulin. Children with psychosocial deprivation had poorer responses to both tests. In view of these findings and the absence of unacceptable side effects with clonidine it is concluded that the oral administration of this alpha-adrenergic stimulant is a safe and reliable alternative test of growth hormone release.
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Among definitive tests of growth hormone (somatotropin) release1 no single stimulus has shown greater reliability than the insulin hypoglycaemia test (IHT), which is the investigation preferred by the United Kingdom's Health Services Human Growth Hormone Committee.2 Although the IHT has the advantage of assessing the hypothalamic-pituitary-adrenal axis in addition to growth hormone (GH) secretion, there is some risk, albeit small, and alternatives have therefore been sought. Oral administration of the alpha-adrenergic drug clonidine has been shown to stimulate GH release in normal subjects3 and was tried successfully by Gil-Ad et al.4 as a test for GH deficiency. In a multicentre trial5 oral clonidine and the IHT were similarly reliable as tests for GH secretion. The purpose of the present study was to compare these two tests in a further series of patients under the more standardised conditions of a single centre.
Patients and methods
Patients. Both tests were performed on 41 patients (30 boys and 11 girls) with short stature (height standard deviation score-3* 0±0* 1, mean ± SEM). The age range was 3 7 to 16-7 years, mean 10 4 years. Seven patients proved to be biochemically GH deficient and a further 6 had distinct clinical disorders affecting growth (Table) . In the remaining 28 the predominant feature was a 'short/delay' pattern of growth, with bone age-21 ±0 -2 years (mean+ SEM less than chronological age).6 Other factors in these 28 patients were extreme familial short stature without maturational delay in 1, low birthweight Cug, and the dosage was rounded up to the nearest number of tablets. Blood pressure was measured half hourly throughout the procedure, and patients were observed in the ward for a further hour before going home.
The IHT was carried out using neutral soluble insulin (Velosulin, Nordisk) in an intravenous dose of 0-15 U/kg bodyweight, except in 3 cases where panhypopituitarism was suspected, when 0 075 U/kg was given. After the IHT all patients were observed overnight. In both procedures samples for GH analysis were taken half hourly for 2j hours through an indwelling intravenous cannula. During the IHTs an additional sample was taken 15 minutes after the insulin injection to confirm hypoglycaemia, and all samples were assayed for glucose and cortisol. In both tests a maximum GH concentration of 15 (Fig. 1) . Figure 2 shows the mean response curves in the 28 patients. The area under the clonidine curve is 1 .5 times that under the IHT curve.
Psychosocial deprivation. Of the 28 patients without GH deficiency, the 10 with known or suspected psychosocial deprivation gave poorer responses to both tests. In the IHT the maximum GH value for these 10 was (mean±SEM) 20 4±3-2 mU/l, compared with 25-2±3-7 mU/1 for the remaining 18 patients. The comparison of results, whereas in the multicentre study several responses were simply expressed as 'greater than'.
In the smaller group of 28 patients with a predominantly 'short/delay' pattern of growth and in whom GH deficiency was excluded because of an adequate GH response to clonidine, subnormal responses to insulin were seen in 7. These false subnormal responses do not seem to be a consequence of a proportionally higher response to clonidine in all patients. Had this been the case, a higher GH value might have been taken as the criterion of normal response in the clonidine test. Indeed, Figure 1 shows that responses to clonidine were similar in those with and without normal responses to insulin. It seems, therefore, that clonidine can more effectively overcome any refractoriness to stimulation which may occur if the basal GH concentration is raised in the range 10-15 mU/l. In such a case a failed response should lead to the test being repeated.
The parents of very small children are naturally protective and the publicity given to rare accidents with the IHT hinders some from consenting to an investigation, which careful clinical and auxological assessment2 has shown to be desirable. The oral clonidine test is a simple, safe alternative procedure during much of which the child is comfortably drowsy. It is unlikely that any test of GH release could give entirely consistent results, but this study shows that clonidine produces false subnormal responses less frequently than insulin and can be recommended as a definitive test of GH secretion.
There remains the possibility that a normal GH response to clonidine may not exclude treatable GH deficiency. Immunologically reactive GH may be biologically inert,17 or the occasional patient may respond to pharmacological stimulation but fail to release GH physiologically.18 It has been suggested that children with psychosocial growth retardation may fall into this last category. 19 Psychosocially deprived children in this series showed reduced, but not significant mean responses both to insulin and to clonidine. The ultimate proof of GH deficiency is in the patient's response to replacement therapy.
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